Why Lyme Disease Remains So Difficult to Diagnose and Why There’s New Reason for Hope

Bay Area Lyme Spotlights Series

Guest Blog by Fred Diamond, author and host of the Love, Hope, Lyme Podcast

“This is solvable. It just needs continued focus.”

– David Walsey, Executive Director, Bay Area Lyme Foundation

For many Lyme disease survivors and families, the journey toward answers can feel overwhelming, confusing, and painfully isolating. Symptoms often linger for years. Tests come back negative despite debilitating illness. Patients bounce from doctor to doctor searching for someone who understands what they are experiencing.

For David Walsey, Executive Director of Bay Area Lyme Foundation, this challenge is deeply personal, as he shared on the Love, Hope, Lyme Podcast.

Before stepping into his leadership role at the Foundation, Walsey and his family spent nearly a decade navigating the complexities of tick-borne illness after one of their children became severely ill.

“It’s really a journey not to wish upon anybody,” Walsey shared. “From getting the diagnosis, to figuring out the treatment, to just knowing really how to treat.”

His family’s experience reflects what countless Lyme survivors endure every year: delayed diagnosis, misunderstood symptoms, co-infections, and the emotional exhaustion that comes from trying to navigate a healthcare system that still struggles to fully understand chronic tick-borne disease.

Why Lyme Disease Is Still So Difficult to Diagnose

One of the biggest challenges facing Lyme patients today is that standard testing methods remain limited, Walsey said.

“The current standard diagnostics are decades old, and they’re looking for an antibody response,” Walsey explained. “Everyone’s immune system is different.”

Most standard Lyme tests do not directly detect the Lyme bacteria itself. Instead, they look for the body’s immune response to infection. That creates enormous variability between patients and often leads to false negatives, especially in the early weeks of illness.”

According to Walsey, recent research involving Lyme Disease Biobank suggests that current testing may miss the majority of early Lyme infections.

“In the first couple of weeks to a month or so, your chances of being properly diagnosed are less than a coin toss,” he said.

That diagnostic uncertainty creates enormous frustration for patients, especially because Lyme symptoms often overlap with numerous other chronic illnesses.

Lyme disease is frequently called “the great imitator” because patients may experience neurological symptoms, fatigue, joint pain, heart issues, cognitive dysfunction, anxiety, sleep disruption, dizziness, or dozens of other symptoms that mimic conditions like fibromyalgia, lupus, rheumatoid arthritis, multiple sclerosis, and chronic fatigue syndrome.

“It becomes very difficult to diagnose,” Walsey said. “The symptoms cycle. You may present differently from one appointment to the next.”

The Complex Role of Co-Infections

Adding to the challenge is the reality that Lyme disease is often only part of the picture.

Many tick-borne illness patients are simultaneously battling co-infections such as Bartonella or Babesia, which can dramatically complicate treatment and recovery.

That was the case for Walsey’s family.

“Treating Lyme really did not move the needle for us,” he said. “First, it was Bartonella we treated. Then once we recognized Babesia and treated Babesia, that’s when we saw significant improvements.”

For many patients, identifying and properly treating co-infections becomes one of the most critical and difficult aspects of recovery.

A New Era of Lyme Research

Despite the immense challenges still facing the Lyme community, Walsey says he is encouraged by the progress happening in Lyme research.

“When I first started talking to Bay Area Lyme about stepping into this role, I was surprised how much the research has advanced, particularly in the last few years,” he said.

Since its founding in 2012, Bay Area Lyme Foundation has invested more than $31 million into research focused on improving Lyme diagnostics and therapeutics. The organization also established Lyme Disease Biobank, a critical research resource providing scientists with carefully characterized patient samples, including blood, urine, and tissue.

According to Walsey, the field is now reaching an important turning point where promising research is beginning to translate into real-world diagnostic tools and treatment possibilities.

“We are starting to see some of those diagnostics reach patients today,” he said.

He believes that within the next several years, the Lyme community may finally see major advances in direct detection testing, including tests capable of identifying active Lyme infection itself rather than relying solely on antibody responses.

Researchers are also working toward tests that could distinguish between active infection and past exposure, something current testing struggles to accomplish.

AI and Biomarker Research Offer New Possibilities

One of the most exciting developments involves the growing use of artificial intelligence and machine learning in Lyme research. Researchers are increasingly analyzing inflammatory biomarkers and immune-system patterns to better distinguish chronic Lyme disease from other conditions with similar symptoms.

“One of the really interesting areas of research is identifying the fingerprint of chronic Lyme versus multiple sclerosis, or rheumatoid arthritis, or fibromyalgia,” Walsey explained.

Researchers are also exploring possible infectious links to other chronic inflammatory and neurodegenerative conditions, including Alzheimer’s disease.

At the same time, new therapeutic strategies are emerging. Some Bay Area Lyme-supported research has explored antibiotic combinations and alternative treatment approaches that may prove more effective than current standard protocols.

One especially promising initiative at Duke University is applying targeted cancer-treatment concepts to Lyme disease through advanced theragnostic research that may eventually improve both diagnosis and treatment.

The Need for Greater Awareness and Funding

While research progress is accelerating, Walsey believes funding remains one of the field’s biggest obstacles. Lyme disease affects an estimated 500,000 Americans annually, according to CDC estimates, yet federal research funding remains disproportionately low compared to many other infectious diseases.

“We really need to step up the funding,” Walsey said. “Not only from government, but from private industry as well.”

He also hopes growing public awareness will help address another painful reality many Lyme patients face: being dismissed or disbelieved.

“At the roundtable in December (convened by HHS Secretary Kennedy), it was noted that these patients are being gaslighted,” he said. “From our own experience, that’s very true.”

Walsey hopes that over the next several years, scientific advances and increased visibility will help eliminate that experience for future patients.

“I’m optimistic that in five years there will be no more gaslighting of patients with Lyme or other tick-borne infections,” he said.

A Message of Hope for Patients and Families

For patients and caregivers currently navigating the uncertainty of Lyme disease, Walsey encourages persistence and self-advocacy. 

“Push for extensive testing,” he advised. “If the symptoms don’t match up with the answer you’re getting, continue to explore what might be driving it.”

He also emphasized that recovery journeys are highly individualized. 

“What works for one patient doesn’t necessarily work for another,” he said. Most importantly, he wants patients to know that real progress is happening.

“I think in three to five years we’re going to be in a materially different place than we are now,” Walsey said. “This is solvable. It just needs continued focus.”

Listen to all episodes of the Love, Hope, Lyme Podcast here or on YouTube.